MYDECINE

Mydecine Innovations Group Adds Dr. Robin Carhart-Harris and Dr. David Erritzoe to Scientific Advisory Board

← Back to all news
August 19, 2020

Published on PsychedelicFinance.com.

DENVER, Colorado, USA, August 19, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" or the"Company"), is pleased to announce that it has added two new strategic advisors to the company's Scientific Advisory Board. The new members of the science team are two of the world’s most notable names in psychedelic research and will be valuable additions to Mydecine’s growing pool of scientific talent.

As advisors they will provide scientific expertise and corporate strategic support as Mydecine launches its R&D program at The Mydecine Center of Mycology(“MYCOM”) in Denver,Colorado, as well as across several specific research initiatives at the University of Alberta through Applied Pharmaceutical Innovations (“API”).

The two new advisors are the renowned scientists, Dr. Robin Carhart-Harris and Dr. David Erritzoe, who currently lead research within the first formal centre for psychedelic research in the world.

A number of research groups across the world have conducted studies into the safety and effectiveness of psychedelics for conditions such as depression and post-traumatic stress disorder (PTSD), but the Imperial Centre for Psychedelic Research is the first to lay the groundwork for larger trials and build advanced psychedelic research capabilities within a major academic institution. The team at Imperial College has pioneered studies including breakthrough neuroimaging research with psilocybin, MDMA, LSD and DMT. The Research Centre focuses on two main research themes: the use of psychedelics in mental health care; and as tools to probe the brain’s basis of consciousness. The centre uses fungtional™ brain imaging to assess how psychedelic compounds work in the brain and also explores their therapeutic potential, with a particular focus on depression.

Rob Roscow, Director and Chief Scientific Officer commented:” We are thrilled to welcome David and Robin to our Scientific Advisory Board. Their deep knowledge of psychedelics will help share our research direction and will be invaluable to helping us achieve our R&D objectives. Collectively, Mydecine’s science team now has an unparalleled level of expertise across psychopharmacology, neuroscience,psychology, neurobiology, and microbiology, and can be expected to continue expanding over the coming months.”

About Dr. Robin Carhart-Harris

Robin Carhart-Harris heads the Centre for Psychedelic Research at Imperial College London, where he has designed a number of functional brain imaging studies with psilocybin (magic mushrooms), LSD, MDMA (ecstasy) and DMT (ayahuasca), two completed clinical trials of psilocybin for depression, totalling 79 patients. Dr. Carhart-Harris has over 90 published papers in peer-reviewed scientific journals; 5 of which rank in the top 10 for annual citation rate in the field of psychedelic science, including the top 2 overall (1,2), and some of these also formally rank among the most impactful scientific papers published in recent years (3-5). By publication rate, the Imperial Centre is also the most productive in the field of psychedelic research. Robin’s research has featured in major national and international media and he has given a popular TEDx talk and made the case for psychedelic medicine at the World Economic Forum in Davos.

Dr. Carhart-Harris first became interested in researching psychedelics after reading Stanislav Grof’s work on LSD while in his masters’ program. Robin became fascinated by the idea of understanding the brain on LSD, and soon began conducting his PhD with a focus on the topic. Dr. Carhart-Harris was the first researcher in the UK to have legally administered LSD to human volunteers since 1971, when the Misuse of Drugs Act was enacted. His research has been supported by a number of notable organizations, including the Beckley Foundation, Neuropsychoanalysis Foundation, the Heffter Foundation, and the Multidisciplinary Association for Psychedelic Studies (MAPS). Robin now regularly presents at conferences around the world and continues to make headlines as he advances the fields of neuroscience and psychedelic medicine through his research.

About Dr. David Erritzoe

Dr. Erritzoe is the Clinical Director of the Centre for Psychedelic Research and is also a member of the Neuropsychopharmacology Research Centre in the Division of Psychiatry at Imperial College London. Dr. David Erritzoe currently holds a NIHR Academic Clinical Lectureship in Psychiatry at Imperial College London, but has recently been appointed as a Senior Clinical Lecturer, a post he will start later in 2020 with Imperial and CNWL NHS Foundation NHS Trust. Alongside his clinical work in medicine/psychiatry, David conducts psychopharmacological research,using brain-imaging techniques such as PET and MRI. David was trained in PET imaging at Columbia University in New York and later undertook a PhD at University Hospital Rigshospitalet in Copenhagen. Since 2009 he has been involved in post-doc imaging research in the neurobiology of addictions and major depression at Imperial, and together with Prof Nutt and Dr Carhart-Harris he investigates mechanisms and therapeutic potential of MDMA and classic psychedelics.

David has specifically been investigating the role and nature of dopamine receptors and neurotransmission in alcohol addiction, studies of opioid neurotransmission in pathological gambling, along with functional imaging studies examining cocaine, alcohol, and heroin addiction. Currently, David runs lab-based multi-modal brain imaging studies [often using pharmacological challenges] focusing on serotonin/dopamine/opiate neurotransmission as well as larger-scale prospective, naturalistic studies with online assessments and/or field-based data collection. Dr. Erritzoe’s research has been featured in major publications and has given a popular TedX talk.

Joshua Bartch, Director and CEO commented: “With these new members, the Mydecine science team is quickly becoming one of the most robust in the industry, and one that is definitively positioned to conduct ground-breaking research and innovation in the psychedelic medicine field.”

About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine,natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution,through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward- looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.

1 Carhart-Harris RL, Bolstridge M,Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B,Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619-27.

2 Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W,Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT,Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, HellyerPJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ (2016)Neural correlates of the LSD experience revealed by multimodal neuroimaging.Proc Natl Acad Sci U S A. 113(17):4853-8. doi: 10.1073/pnas.1518377113.

3 https://www.altmetric.com/details/7563218/blogs

4 https://www.altmetric.com/details/27392661

5 https://www.altmetric.com/details/6615140